Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
| Autor: | Saundra S. Buys, M. Daly, P. D. P Pharoah, M S Piver, Ingrid Oakley-Girvan, Alice S. Whittemore, Richard A. DiCioccio, Raymond R. Balise, M B Usinowicz, John L. Hopper, Ruby T. Senie, Esther M. John, Susan J. Ramus, Irene L. Andrulis, Kim Garlinghouse-Jones, B. A. J. Ponder |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
oral contraceptives ovarian cancer Heterozygote Cancer Research medicine.medical_specialty endocrine system diseases Epidemiology Genes BRCA2 Population Genes BRCA1 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors medicine Humans Neoplasm Invasiveness Neoplasms Glandular and Epithelial 030212 general & internal medicine education Germ-Line Mutation Ovarian Neoplasms Gynecology education.field_of_study Obstetrics business.industry Case-control study Cancer Odds ratio Middle Aged BRCA1 medicine.disease BRCA2 3. Good health Clinical research Oncology Family planning Case-Control Studies 030220 oncology & carcinogenesis Female Ovarian cancer business Contraceptives Oral |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6602239 |
| Popis: | Women with mutations of the genes BRCA1 or BRCA2 are at increased risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they protect against the disease in carriers of these mutations. We obtained self-reported lifetime histories of oral contraceptive use from 451 women who carried mutations of BRCA1 or BRCA2. We used conditional logistic regression to estimate the odds ratios associated with oral contraceptive use, comparing the histories of 147 women with ovarian cancer (cases) to those of 304 women without ovarian cancer (controls) who were matched to cases on year of birth, country of residence and gene (BRCA1 vs BRCA2). Reference ages for controls had to exceed the ages at diagnosis of their matched cases. After adjusting for parity, the odds-ratio for ovarian cancer associated with use of oral contraceptives for at least 1 year was 0.85 (95 percent confidence interval, 0.53-1.36). The risk decreased by 5% (1-9%) with each year of use (P for trend=0.01). Use for 6 or more years was associated with an odds-ratio of 0.62 (0.35-1.09). These data support the hypothesis that long-term oral contraceptive use reduces the risk of ovarian cancer among women who carry mutations of BRCA1 or BRCA2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|